Overall, though, the presence of cross-presenting cDC1s within the tumor is usually associated with a better prognosis (197) arguing that tumor infiltrating cDC1s typically contribute to CD8+ T cell priming rather than tolerance. The gene discussed is CD8A; the disease is neoplasm.